Data on more than 900 patients with type 2 diabetes showed those who took exenatide once-weekly for 26 weeks attained an average decrease of 1.28% in hemoglobin A1c levels, while those who took liraglutide once-daily for the same period had a 1.48% reduction in HbA1c rates. The exenatide group also had a mean weight loss of almost 6 pounds, while liraglutide-treated patients lost almost 8 pounds.

Related Summaries